MiNK <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures NIAID Grant to Advance Allo-iNKT Cell Therapy for GvHD Prevention in Collaboration with University of Wisconsin
MiNK Therapeutics Inc., a clinical-stage biopharmaceutical company, has been awarded a prestigious grant from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). This non-dilutive funding will support the development of MiNK's allogeneic invariant natural killer T (iNKT) cell therapy platform, aimed at preventing and treating graft-versus-host disease (GvHD) following hematopoietic stem cell transplantation $(HSCT)$. The grant is a collaborative effort with the University of Wisconsin, highlighting the partnership between MiNK's iNKT manufacturing capabilities and the university's expertise in transplant immunology. This funding underscores the promise of iNKT cells in immune regulation and accelerates the development of therapies for a significant unmet medical need.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461636-en) on June 02, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。